文献速递围术期管理与 ERAS

腹主动脉瘤腔内修复术中长期结果:单中心10年经验

[Mid- and long-term results of endovascular aneurysm repair for abdominal aortic aneurysms: a single center's experience for 10 years].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2020-01-01

该回顾性队列纳入2009至2018年单中心540例腹主动脉瘤EVAR患者,技术成功率91.1%,围手术期病死率1.3%,随访期间全因病死率21.3%、动脉瘤相关病死率6.3%,高龄、术前破裂和短瘤颈是远期生存独立预后因素。

要点

  • EVAR围手术期病死率1.3%,技术成功率91.1%。
  • 随访全因病死率21.3%,动脉瘤相关病死率6.3%。
  • 高龄、术前破裂、短瘤颈提示远期生存更差。

核心结论

  • EVAR治疗腹主动脉瘤围手术期病死率低、技术成功率高,中远期结果良好。

研究设计与样本

  • 回顾性队列研究,纳入2009年1月至2018年12月单中心540例接受EVAR的腹主动脉瘤患者。
  • 男性503例、女性37例,年龄(69±8)岁(范围44~87岁),随访率91.7%(489/533),中位随访45(63)个月(范围1~133个月)。

主要发现

  • 技术成功率91.1%(492/540),围手术期病死率1.3%(7/540)。
  • 随访期间全因病死率21.3%(104/489),动脉瘤相关病死率6.3%(31/489)。
  • 1、3、5、10年累积总体生存率分别为95.1%、84.0%、69.5%、38.6%,免于动脉瘤病死率分别为98.4%、93.3%、88.4%、84.4%。
  • 随访期间并发症发生率9.0%(44/489),二次干预率4.9%(24/489)。
  • 高龄(HR=2.15,95%CI:1.41~3.26,P<0.01)、术前动脉瘤破裂(HR=2.72,95%CI:1.78~4.15,P<0.01)、短瘤颈(HR=1.97,95%CI:1.07~3.61,P=0.029)是远期生存独立预后因素。

临床怎么用

  • 对高龄、术前破裂或短瘤颈的腹主动脉瘤患者行EVAR时,应加强远期生存评估与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To examine the mid- and long-term outcomes of endovascular aneurysm repair (EVAR). Methods: This was a retrospective cohort study of 540 patients with abdominal aortic aneurysm who received EVAR at Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University from January 2009 to December 2018. There were 503 males and 37 females, aged of (69±8) years (range: 44 to 87 years). Clinical data including concomitant disease, aneurysm size and surgical data were collected and patients were followed up after operation. The cumulative survival rate was assessed using the Kaplan-Meier estimator and multivariate Cox regression was used to analyze the independent prognosis factors. Results: The technical success rate was 91.1% (492/540). The perioperative mortality rate was 1.3% (7/540) and the follow-up rate was 91.7% (489/533). The median follow-up time was 45(63) months (range: 1 to 133 months). The all-cause mortality rate was 21.3% (104/489) and the aneurysm-related mortality rate was 6.3% (31/489) during follow-up period. The overall cumulative survival rate of 1-, 3-, 5- and 10-year were 95.1%, 84.0%, 69.5% and 38.6%, respectively, while freedom from aneurysm-related death were 98.4%, 93.3%, 88.4% and 84.4%. During the follow-up period, the complications rate was 9.0% (44/489), and the re-intervention rate was 4.9% (24/489). Cox regression analysis showed that elder age (HR=2.15, 95%CI: 1.41 to 3.26, P<0.01), preoperative aneurysm rupture (HR=2.72, 95%CI: 1.78 to 4.15, P<0.01) and short neck aneurysm (HR=1.97, 95%CI: 1.07 to 3.61, P=0.029) were independent prognosis factors for long-term survival after EVAR. Connclusion: EVAR has low perioperative mortality, high technical success rate, and satisfactory mid-and long-term outcomes. 目的: 探讨腹主动脉瘤腔内修复术(EVAR)的中长期治疗效果。 方法: 回顾性分析2009年1月至2018年12月540例在中山大学附属第一医院血管外科接受EVAR治疗的腹主动脉瘤患者的临床资料。男性503例,女性37例,年龄(69±8)岁(范围:44~87岁)。收集患者合并症、术前动脉瘤参数、手术数据等资料,并对患者进行术后随访,了解患者术后生存、并发症发生及二次干预等情况。应用Kaplan-Meier法计算累积生存率,Cox多元回归分析远期生存预后因素。 结果: 492例获得技术成功,技术成功率为91.1%(492/540)。围手术期病死率为1.3%(7/540)。489例获得随访,随访率为91.7%(489/533)。随访时间45(63)个月(范围:1~133个月)。随访期间全因死亡104例,动脉瘤相关死亡31例,全因病死率21.3%(104/489),动脉瘤相关病死率6.3%(31/489)。1、3、5和10年累积总体生存率分别为95.1%、84.0%、69.5%和38.6%,免于动脉瘤病死率分别为98.4%、93.3%、88.4%和84.4%。随访期间手术相关并发症发生率为9.0%(44/489),二次干预率为4.9%(24/489)。多因素分析结果显示,高龄(HR=2.15,95%CI:1.41~3.26,P<0.01)、术前动脉瘤破裂(HR=2.72,95%CI:1.78~4.15,P<0.01)和短瘤颈(HR=1.97,95%CI:1.07~3.61,P=0.029)是EVAR术后远期生存的独立预后因素。 结论: EVAR治疗后患者的围手术期病死率低,技术成功率高,具有良好的中远期结果。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang R, Yao C, Wang JS, et al. [Mid- and long-term results of endovascular aneurysm repair for abdominal aortic aneurysms: a single center's experience for 10 years]. Zhonghua Wai Ke Za Zhi. 2020. PMID: 33120446. doi:10.3760/cma.j.cn112139-20200628-00500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。